Tumor Immune Microenvironment in Lymphoproliferative Syndromes
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: closed (31 January 2022) | Viewed by 17970
Special Issue Editors
Interests: molecular pathology; molecular genetics; biotechnology; lymphoma biology
Interests: immunology; immunotherapy; lymphoma; melanoma; breast cancer; immune biomarkers discovery
Special Issue Information
Dear Colleagues,
Lymphoproliferative syndromes constitute an extensive and heterogeneous group of oncological diseases with different features, biological behavior, and clinical evolution. The precise molecular characterization of lymphomas is gaining in interest and relevance, as it may represent the first step in the design a successful therapeutic strategy to keep disease under control. However, the complexity of lymphomas goes beyond the molecular abnormalities of malignant lymphocytes. The specific surrounding tumor microenvironment (TME) has been revealed as a factor of paramount relevance, that in some cases harbors prognostic and predictive information which can be crucial from a clinical perspective, as the availability of different types of immunotherapies has dramatically increased in the last few years.
In this Special Issue, reputed basic and clinical experts in the lymphoma field will try to thoroughly describe the specific immune TME in these diseases, from different angles, in order to identify potential new therapeutic targets that could ameliorate clinical outcomes in patients with lymphoproliferative syndromes.
Dr. Margarita Sánchez-Beato
Dr. Luis De la Cruz-Merino
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumor microenvironment
- immune cells
- therapeutic targets
- immunotherapy
- lymphomas
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.